XML 103 R49.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaborative and Other Relationships (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Co-promotion profit sharing formula | Our share of annual co-promotion profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until GAZYVA First Non-CLL FDA Approval | 40.0 | %
After GAZYVA First Non-CLL FDA Approval until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Pretax profit sharing formula | Our share of annual profits in excess of $50.0 million varies, as summarized in the table below, upon the following events:
Until First GAZYVA Threshold Date | 39.0 | %
After First GAZYVA Threshold Date until Second GAZYVA Threshold Date | 37.5 | %
After Second GAZYVA Threshold Date | 35.0 | %
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA |  | $ | 1,080.2 |  |  | $ | 1,542.4 |  |  | $ | 1,431.9 |
Other revenues from anti-CD20 therapeutic programs |  | 897.6 |  |  | 748.0 |  |  | 548.3 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 1,977.8 |  |  | $ | 2,290.4 |  |  | $ | 1,980.2 |
Revenues from anti-CD20 therapeutic programs are summarized as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses |  | $ | 1,080.2 |  |  | $ | 1,542.4 |  |  | $ | 1,431.9 |
Other revenues from anti-CD20 therapeutic programs |  | 897.6 |  |  | 748.0 |  |  | 548.3 |
Total revenues from anti-CD20 therapeutic programs |  | $ | 1,977.8 |  |  | $ | 2,290.4 |  |  | $ | 1,980.2 |
Summary of activity related to BAN2401 and Elenbecestat collaboration | A summary of development and sales and marketing expenses related to the BAN2401 Collaboration is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Total development expense incurred by the collaboration related to the advancement of BAN2401 and elenbecestat |  | $ | 219.3 |  |  | $ | 348.7 |  |  | $ | 232.0 |
Biogen's share of BAN2401 and elenbecestat development expense reflected in research and development expense in our consolidated statements of income |  | 109.6 |  |  | 174.3 |  |  | 116.0 |
Total sales and marketing expense incurred by the collaboration |  | 9.8 |  |  | 32.4 |  |  | 10.7 |
Biogen's share of BAN2401 and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income |  | 4.9 |  |  | 16.2 |  |  | 5.4 |
Summary of activity related to Aducanumab collaboration | A summary of development, sales and marketing and milestone expense related to the Aducanumab Collaboration Agreement is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Total aducanumab development expense |  | $ | 152.0 |  |  | $ | 179.4 |  |  | $ | 264.8 |
Biogen's share of aducanumab development expense reflected in research and development expense in our consolidated statements of income |  | 83.6 |  |  | 98.7 |  |  | 234.6 |
Total aducanumab sales and marketing expense incurred by the collaboration |  | 353.0 |  |  | 27.4 |  |  | 50.6 |
Biogen's share of aducanumab sales and marketing expense reflected in selling, general and administrative expense in our consolidated statements of income |  | 193.7 |  |  | 15.1 |  |  | 27.3 |
Total aducanumab collaboration third party milestone expense |  | 75.0 |  |  | — |  |  | — |
Eisai's share of aducanumab milestone expense reflected in collaboration profit sharing in our consolidated statements of income |  | 33.8 |  |  | — |  |  | — |
Summary of activity related to the UCB collaboration | A summary of development expense related to the UCB collaboration agreement is as follows:
|  | For the Years Ended December 31,
(In millions) |  | 2020 |  | 2019 |  | 2018
Total UCB development expense |  | $ | 58.3 |  |  | $ | 31.9 |  |  | $ | 29.7 |
Biogen's share of UCB development expense reflected in research and development expense in our consolidated statements of income |  | 29.2 |  |  | 16.0 |  |  | 14.9 |

X
- Definition Co-promotion profit sharing formula. + References No definition available. + Details
Name: | biib_CoPromotionProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Pretax Profit Sharing Formula [Table Text Block] + References No definition available. + Details
Name: | biib_PretaxProfitSharingFormulaTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary Of Activity Related To Collaboration With Company Eight [Table Text Block] [Table Text Block] + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToCollaborationWithCompanyEightTableTextBlockTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of Activity Related to the UCB Collaboration + References No definition available. + Details
Name: | biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition [Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table] + References No definition available. + Details
Name: | biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration